Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 231

1.

miR-199a-3p inhibits aurora kinase A and attenuates prostate cancer growth: new avenue for prostate cancer treatment.

Qu Y, Huang X, Li Z, Liu J, Wu J, Chen D, Zhao F, Mu D.

Am J Pathol. 2014 May;184(5):1541-9. doi: 10.1016/j.ajpath.2014.01.017. Epub 2014 Mar 11.

PMID:
24631181
2.

Genistein up-regulates tumor suppressor microRNA-574-3p in prostate cancer.

Chiyomaru T, Yamamura S, Fukuhara S, Hidaka H, Majid S, Saini S, Arora S, Deng G, Shahryari V, Chang I, Tanaka Y, Tabatabai ZL, Enokida H, Seki N, Nakagawa M, Dahiya R.

PLoS One. 2013;8(3):e58929. doi: 10.1371/journal.pone.0058929. Epub 2013 Mar 12.

3.

MicroRNA-199a-3p regulates endometrial cancer cell proliferation by targeting mammalian target of rapamycin (mTOR).

Wu D, Huang HJ, He CN, Wang KY.

Int J Gynecol Cancer. 2013 Sep;23(7):1191-7. doi: 10.1097/IGC.0b013e31829ea779.

PMID:
23851675
4.

MicroRNA-466 inhibits tumor growth and bone metastasis in prostate cancer by direct regulation of osteogenic transcription factor RUNX2.

Colden M, Dar AA, Saini S, Dahiya PV, Shahryari V, Yamamura S, Tanaka Y, Stein G, Dahiya R, Majid S.

Cell Death Dis. 2017 Jan 26;8(1):e2572. doi: 10.1038/cddis.2017.15.

5.

Meta-analysis of miRNA expression profiles for prostate cancer recurrence following radical prostatectomy.

Pashaei E, Pashaei E, Ahmady M, Ozen M, Aydin N.

PLoS One. 2017 Jun 26;12(6):e0179543. doi: 10.1371/journal.pone.0179543. eCollection 2017.

6.

The deoxycholic acid targets miRNA-dependent CAC1 gene expression in multidrug resistance of human colorectal cancer.

Kong Y, Bai PS, Sun H, Nan KJ, Chen NZ, Qi XG.

Int J Biochem Cell Biol. 2012 Dec;44(12):2321-32. doi: 10.1016/j.biocel.2012.08.006. Epub 2012 Aug 10.

PMID:
22903020
7.

The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma.

Kinose Y, Sawada K, Nakamura K, Sawada I, Toda A, Nakatsuka E, Hashimoto K, Mabuchi S, Takahashi K, Kurachi H, Lengyel E, Kimura T.

Oncotarget. 2015 May 10;6(13):11342-56.

8.

SNHG1 lncRNA negatively regulates miR-199a-3p to enhance CDK7 expression and promote cell proliferation in prostate cancer.

Li J, Zhang Z, Xiong L, Guo C, Jiang T, Zeng L, Li G, Wang J.

Biochem Biophys Res Commun. 2017 May 20;487(1):146-152. doi: 10.1016/j.bbrc.2017.03.169. Epub 2017 Apr 8.

PMID:
28400279
9.

Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis.

Saini S, Majid S, Yamamura S, Tabatabai L, Suh SO, Shahryari V, Chen Y, Deng G, Tanaka Y, Dahiya R.

Clin Cancer Res. 2011 Aug 15;17(16):5287-98. doi: 10.1158/1078-0432.CCR-10-2619. Epub 2010 Dec 15.

10.

Metformin inhibits epithelial-mesenchymal transition in prostate cancer cells: involvement of the tumor suppressor miR30a and its target gene SOX4.

Zhang J, Shen C, Wang L, Ma Q, Xia P, Qi M, Yang M, Han B.

Biochem Biophys Res Commun. 2014 Sep 26;452(3):746-52. doi: 10.1016/j.bbrc.2014.08.154. Epub 2014 Sep 6.

PMID:
25201727
11.

MicroRNA miR-199a* regulates the MET proto-oncogene and the downstream extracellular signal-regulated kinase 2 (ERK2).

Kim S, Lee UJ, Kim MN, Lee EJ, Kim JY, Lee MY, Choung S, Kim YJ, Choi YC.

J Biol Chem. 2008 Jun 27;283(26):18158-66. doi: 10.1074/jbc.M800186200. Epub 2008 May 2.

12.

MicroRNA miR-199a-3p regulates cell proliferation and survival by targeting caveolin-2.

Shatseva T, Lee DY, Deng Z, Yang BB.

J Cell Sci. 2011 Aug 15;124(Pt 16):2826-36. doi: 10.1242/jcs.077529.

13.

MiR-199a-3p enhances breast cancer cell sensitivity to cisplatin by downregulating TFAM (TFAM).

Fan X, Zhou S, Zheng M, Deng X, Yi Y, Huang T.

Biomed Pharmacother. 2017 Apr;88:507-514. doi: 10.1016/j.biopha.2017.01.058. Epub 2017 Jan 23.

PMID:
28126676
14.

MiR-203 down-regulates Rap1A and suppresses cell proliferation, adhesion and invasion in prostate cancer.

Xiang J, Bian C, Wang H, Huang S, Wu D.

J Exp Clin Cancer Res. 2015 Jan 31;34:8. doi: 10.1186/s13046-015-0125-x.

15.

MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells.

Fornari F, Milazzo M, Chieco P, Negrini M, Calin GA, Grazi GL, Pollutri D, Croce CM, Bolondi L, Gramantieri L.

Cancer Res. 2010 Jun 15;70(12):5184-93. doi: 10.1158/0008-5472.CAN-10-0145. Epub 2010 May 25.

16.

MiR-199a-3p promotes gastric cancer progression by targeting ZHX1.

Wang Z, Ma X, Cai Q, Wang X, Yu B, Cai Q, liu B, Zhu Z, Li C.

FEBS Lett. 2014 Nov 28;588(23):4504-12.

17.

MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway.

Hsieh IS, Chang KC, Tsai YT, Ke JY, Lu PJ, Lee KH, Yeh SD, Hong TM, Chen YL.

Carcinogenesis. 2013 Mar;34(3):530-8. doi: 10.1093/carcin/bgs371. Epub 2012 Nov 26.

PMID:
23188675
18.

miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer.

Su SF, Chang YW, Andreu-Vieyra C, Fang JY, Yang Z, Han B, Lee AS, Liang G.

Oncogene. 2013 Sep 26;32(39):4694-701. doi: 10.1038/onc.2012.483. Epub 2012 Oct 22.

19.

MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma.

Boll K, Reiche K, Kasack K, Mörbt N, Kretzschmar AK, Tomm JM, Verhaegh G, Schalken J, von Bergen M, Horn F, Hackermüller J.

Oncogene. 2013 Jan 17;32(3):277-85. doi: 10.1038/onc.2012.55. Epub 2012 Mar 5.

PMID:
22391564
20.

Identification of miR-30d as a novel prognostic maker of prostate cancer.

Kobayashi N, Uemura H, Nagahama K, Okudela K, Furuya M, Ino Y, Ito Y, Hirano H, Inayama Y, Aoki I, Nagashima Y, Kubota Y, Ishiguro H.

Oncotarget. 2012 Nov;3(11):1455-71.

Supplemental Content

Support Center